### Comment:
Black box label for sure, that's what we've got on the SGLT2 inhibs. I see it as getting approved but not used much. They didn't research all cause mortality which they should have, so that will limit how much they use it. I wanted to read their entire clinical trials history on the drug but they didnt publish any results, which annoys me and is a negative sign for me. Regardless I snagged a few shares to see the pop for approval. If it doesn't then I'll just bag hold for a while.

### REPLY:
I agree with you as t1d. My intuition is saying very low market for this drug. When trying to improve ha1c's, there's a multitude of steps to take which don't carry the side-effects of these inhibitors. They seem like a last resort for individuals with highly sensitive blood glucose responses. CGM tech has greater a1c reductions, but without these risks.

### END.